Tarlatamab in Advanced DLL3-Expressing Tumors Including Neuroendocrine Neoplasms
Latest Information Update: 03 Feb 2025
Price :
$35 *
At a glance
- Drugs Tarlatamab (Primary)
- Indications Carcinoma; Gastrointestinal cancer; Neuroendocrine carcinoma; Pancreatic cancer; Small cell lung cancer
- Focus Therapeutic Use
- 03 Feb 2025 New trial record